Sign in

CIK 0000727510

  • Non-accelerated filer
  • Smaller reporting company

Viskase Holdings, Inc.

Sign in to watch
Ticker
VISK
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
222372868
Phone
+1 630-874-0700
Business address
333 EAST BUTTERFIELD ROAD, SUITE 400, LOMBARD, IL, 60148
Former names
ENZON PHARMACEUTICALS, INC., ENZON PHARMACEUTICALS INC, ENZON PHARMACEUTICALS INC, ENZON PHARMACEUTICAL INC, ENZON INC
  1. 4 Exercise or conversion EVP, Technical Operations acquired 12,600 shares (option exercise)
  2. 4 Open-market sale Exec. Vice Pres. HR sold 2,826 shares at $6.12 ($17,295)
  3. 4 Open-market sale EVP, R&D, Chief Scientific Off sold 7,035 shares at $6.12 ($43,054)
  4. 4 Shares withheld for taxes Chairman of the Board & CEO gave up 27,011 shares (to pay taxes)
  5. 4 Open-market sale Exec VP Finance, CFO sold 10,306 shares at $6.33 ($65,237)
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Exercise or conversion Chairman, CEO & President acquired 36,000 shares (option exercise)
  14. 4 Exercise or conversion EVP, R&D, Chief Scientific Off acquired 2,250 shares (option exercise)
  15. 4 Exercise or conversion Exec. Vice Pres. HR acquired 3,000 shares (option exercise)
  16. 4 Exercise or conversion Exec VP Finance, CFO acquired 3,000 shares (option exercise)
  17. 4 Exercise or conversion EVP - Technical Operations acquired 3,000 shares (option exercise)
  18. 4 Open-market buy Director bought 10,000 shares at an average $4.06 ($40,552)
  19. 4 Open-market buy Director bought 15,000 shares at $3.77 ($56,514)
  20. 4 Open-market buy Director bought 10,000 shares at an average $3.64 ($36,429)

Page 11 of 28 · 560 filings